|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Johnson & Johnson (NYSE:JNJ), a provider of healthcare products and services to the consumer, pharmaceutical, medical devices, and diagnostics markets. |
|---|---|
| Transferring Party | ColBar LifeScience, an Israeli-based based, venture-backed producer of collagen implants. |
| Sector | Biopharmaceuticals |
| Date | March 15, 2006 |
| Analysis J&J accesses two promising ColBar collagen products in fast growing artificial tissue segments: one for encouraging bone growth in the jaw for dental applications and the other for treating facial wrinkles (the aesthetic market). Pipeline products address urological, orthopedic and other fields. Deal value $140m. ColBar’s has several million dollars in sales, mostly in Europe. Subject to closing conditions. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |